Project management consulting

We supported Vaccines Europe, a vaccine group within EFPIA (European Federation of Pharmaceutical Industries and Associations) in mobilizing a consortium of vaccine manufacturers and institutions to build together an innovative “European Vaccine Roadmap” for the next 5 years.

Our team played the role of project manager in order to 1) bring together the visions of the different vaccine players mobilized, 2) co-write the roadmap with all of them 3) while ensuring the alignment between all and the coherence of the suggested directions.

The result for our client? A consortium of aligned players, a clear and ambitious collaborative roadmap, and a shared innovation project! Find all the information about this project and the details of the roadmap here: http://iprove-roadmap.eu/

Our team assisted a pharmaceutical player who found that his innovation process was not agile and efficient enough. We first exchanged with our client’s teams to get a detailed understanding of what was working well and to identify the malfunctions of the initial process.

Then, we identified inspiring cases from industries outside healthcare but facing the same issues and we defined the guiding principles of the new process to be implemented. With this material, we organized a “Sprint” bringing together about twenty representatives from the various departments and functions involved in innovation, in order to co-build the new model following the precepts of Design Thinking.

Ultimately, this work enabled us to co-construct with our client’s teams their new innovation process, more focused and more agile at the same time, allowing more disruption and empowerment of the teams!

Our team assisted one of our clients in the redefinition of the contract of objectives and means of a leading Living Lab in France in the field of health and autonomy.

The main objective of our project was to rethink the role of the Living Lab in order to facilitate and streamline the conduct of its collaborative projects. Our support allowed the prioritization of the Living lab’s strategic fields of action, the identification of collaborative projects with high added value, the review of the governance and the construction of a monitoring strategy.

This work made it possible to “reassure” investors while maintaining a certain amount of flexibility, and also enabled to realign all the teams towards the same objective.

Alcimed worked with a top pharmaceutical client to develop a comprehensive process and project management product-specific tool to plan and prioritize actions at the right timing to efficiently launch multiple products on hematology in a short timeframe.

At first, our team defined a clear vision of what the tool should be, key parameters, required data, and future use cases, including format, information granularity, and outputs desired. We then proceeded to define a set of operational activities (e.g. segmentation and targeting strategy, environmental field campaign, product availability, etc.) for the launch of a product to be implemented in the tool. For each activity, all the relevant steps for the launch of the product, the process evolution criteria, and associated decision processes were characterized and implemented in the final version of the tool.

In the end, we built a product-specific project management tool to optimize the process of the launch of several products within a short period. The intuitive and easy-to-use tool provided a clear visualization of the potential bottlenecks, teams’ planning, and the different activities details (“to-do lists”), enabling our client to sequence and optimize their product launches.

Alcimed assisted an American biopharmaceutical client in defining the launch strategy of its orphan drug in Europe, and then in structuring a concrete and operational plan, both at the level of the European region and at the level of each targeted country.

The launch plan is a roadmap for each of the company’s key functions (medical, marketing, production, regulatory, sales) and covers the period from pre-launch (before obtaining the MA – Marketing Authorization) to the first sales.

Today, our team is still involved in regularly updating the first plan defined with our client, according to internal or external developments around this orphan drug in several European countries.

For nearly 2 years, Alcimed has supported a company leader in the aeronautics industry in the definition of its project roadmap for the implementation of its 4.0 plant and the operational deployment of this new factory.

To carry out this project, our team first identified via a benchmark the most relevant organization models and technologies to consider, then we selected the most interesting external service providers for our client, and we finally defined the articulation and the schedule of the different worksites.

Once the final roadmap was validated, our team piloted, monitored and led the different working groups in charge of the various projects, to deliver the first operational results 12 months later!

Alcimed has accompanied AIRe in the design and deployment of an experiment on the functioning of an integrated ITEP device in 6 French regions, in order to streamline the pathways of the children and teenagers received, by proposing the most adapted response to their needs.

At the end of this 2-year experiment, Alcimed then conducted an evaluation of the system through a detailed analysis of the service provided.

Aware of the value of this integrated “out-of-home” system, the legislator has incorporated it into practice through the publication of a dedicated decree.

Our team has assisted project leaders in the preparation of a “Eurostars” funding application and the search for French and European industrial partners. Alcimed carried out a diagnosis of the current state of the project and then assisted the project leaders in identifying and structuring partnerships (establishing contacts and developing the consortium).

Following this, we wrote the response file to the call for projects (AAP), in collaboration with the project leaders on the non-scientific parts, and proceeded to a global critical review, until the final file was sent. Our support allowed our client to structure its approach from A-to-Z and to guarantee an optimization of the content and form of its financial file.